Aquestive Therapeutics, Inc. cash flow to debt ratio of -39.89% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Aquestive Therapeutics, Inc.'s free cash flow has decreased 47.54% from $-35.92M last year to $-52.99M, signaling decreasing performance

Aquestive Therapeutics, Inc.'s debt to equity ratio is -3.92, signaling that the company spent its equity and risk bankruptcy.

Aquestive Therapeutics, Inc.'s debt to equity ratio is -3.92, signaling that the company spent its equity and risk bankruptcy.

Aquestive Therapeutics, Inc. has negative EBITDA, making leverage ratio unreliable

Aquestive Therapeutics, Inc.'s interest coverage ratio is -3.34, which means that the company struggles to meet interest obligations, signaling financial risk.

Aquestive Therapeutics, Inc.'s profit margin has decreased (78.77%) in the last year from -76.68% to -137.08%, signaling decreasing performance

Aquestive Therapeutics, Inc.'s short-term assets of $149.27M exceed its short-term liabilities of $47.61M

Aquestive Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Aquestive Therapeutics, Inc.'s return on equity of 190.87%, is higher than 15.00%, indicating good performance

Aquestive Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Aquestive Therapeutics, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Aquestive Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Aquestive Therapeutics, Inc. has negative free cash flow, indicating cash burn

Aquestive Therapeutics, Inc.'s yearly earnings has decreased 89.83% since last year from $-44.14M to $-83.78M, signaling decreasing performance

Aquestive Therapeutics, Inc.'s yearly revenue has decreased 22.61% since last year from $57.56M to $44.55M, signaling decreasing performance

ROIC -44.82% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Aquestive Therapeutics, Inc.'s 3-year revenue CAGR of -2.24% is negative, indicating declining revenue over the past 3 years

Aquestive Therapeutics, Inc. had revenue growth in 3 out of 5 years, indicating consistent revenue performance

Aquestive Therapeutics, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Aquestive Therapeutics, Inc. has insufficient data to evaluate this check.

Aquestive Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Aquestive Therapeutics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Aquestive Therapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Aquestive Therapeutics, Inc. is overvalued relative to its fair value price of -1.67 based on Earnings Fair Value model

Aquestive Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Aquestive Therapeutics, Inc. has negative shareholder equity; price-to-book is not meaningful and the check fails

Aquestive Therapeutics, Inc. has a price-to-sales ratio of 10.46x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue